组蛋白去乙酰化酶2在脑胶质瘤中的表达及其临床意义  

Expression and significance of histone deacetylase 2 in astrocytomas

作　　者：王俊文[1] 李俊[1] 韩林[2] 胡玲[1] 吴志敏[1] 陈智[1] 熊左隽[1] 陈文[1] 

机构地区：[1]华中科技大学同济医学院附属武汉市中心医院神经外科,武汉430014 [2]华中科技大学同济医学院附属同济医院神经外科

出　　处：《中华实验外科杂志》2013年第5期967-970,共4页Chinese Journal of Experimental Surgery

基　　金：基金项目：国家自然科学基金资助项目（81101620）;武汉市科技局科技攻关计划资助项目（201260523187-3）

摘　　要：目的探讨组蛋白去乙酰化酶2（HDAC2）在星形细胞瘤中的表达及其临床意义。方法收集283例WHOⅡ～Ⅳ级原发性星型细胞瘤标本和52例复发病例肿瘤标本，其中Ⅱ级59例，Ⅲ级26例，Ⅳ级250例。运用免疫组织化学和免疫荧光法探讨HDAC2在星型细胞瘤中的表达和分布。提取肿瘤组织、肿瘤干细胞和胶质瘤细胞株细胞RNA进行半定量逆转录-聚合酶链反应（RT—PCR）分析HDAC2表达水平。结果约85．6％的肿瘤细胞核阳性表达HDAC2，大约33．5％的肿瘤中有超过75．0％的肿瘤细胞阳性表达HDAC2。在10组WHO病理级别升高的标本中，可见HDAC2的表达强度在1例中减弱，在7例中增强，在其他2例中的差异无统计学意义（P〉0．05）。在23组WHO病理级别无差异的复发肿瘤标本中，可见HDAC2的表达强度在6例中减弱，在10例中增强，在其他7例中差异无统计学意义（P〉0．05）。HDAC2仅仅表达于肿瘤细胞，内皮细胞和小胶质细胞都没有HDAC2的表达。HDAC2的表达与细胞核增殖抗原（Ki-67）的表达密切相关（P〈0．01）。在WHOⅣ级病例中，HDAC2的表达与患者预后临界相关[风险比（HR）=0．7343，95％可信区间（CI）（0．5252～1．0470）；P〉0．05]。低于75．0％瘤细胞HDAC2表达的病例的中位生存时间为425d，远远高于超过75．0％瘤细胞表达HDAC2的病例的350d。结论HDAC2在星形细胞瘤细胞增殖中发挥了重要作用。Objective To investigate the expression and significance of histone deacetylase 2 （ HDAC2 ） in astrocytomas. Methods Samples from 283 cases of primary gliomas with WHO Ⅱ -Ⅳ and 52 cases of recurrent tumors were collected. Histopathologically, there were 59 cases of low-grade gliomas （ grade Ⅱ ） and 276 cases of high-grade gliomas （26 cases of grade m and 250 cases of glioblastomas）. The expression of HDAC1 was immunohistochemically detected and its correlation with tumor differentiation, tumor proliferation and survival was analyzed. Results Totally, 85.6% of the tumors showed nuclear expression, and about 33.5% of them showed more than 75.0% nuclear expression. In these individuals who underwent tumor relapse with increasing in WHO grade, 10 of them could be evaluated after stainning procedure. The immunoreactivity was decreased with tumor progression only in 1 case, remained stable immunoreactivity in 2 cases, and increased in 7 cases. In these individuals who underwent tumor relapse without increasing in WHO grade, 23 of them could be evaluated, and HDAC2 immunoreactivity was decreased in 6 eases, remained stable in 7 eases and inereased in the other 10 cases. HDAC2 was not expressed in endothelial or mieroglia cells, and only expressed in tumor eells. There was significant association between HDAC2 and proliferation eell nuclear antigen （Ki-67） expression. In WHO grade IV subgroup, HDAC2 expression showed a borderline significance with shortened overall survival [ hazard ratio （HR） =0. 7343, 95% eorlfidence interval（CI） （0. 5152 to 1. 0470） ;P 〉0. 05]. And the median survival in GBM patients with less than 75.0% nuclear HDAC2 expression was 425 days as compared to 350 days in GBM patients with more nuclear HDAC2 expression. Conclusion There was a signifieant association between HDAC2 expression and astroeytoma proliferation.

关 键 词：组蛋白去乙酰化酶2 星形细胞瘤 表达 

分 类 号：R73[医药卫生—肿瘤]